Phase I study of MK-954, a new angiotensin II receptor antagonist. Results of single oral administration

Authors
Category Primary study
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Year 1995
This article has no abstract
Epistemonikos ID: cce97047bfd5a044eb788e296509bf18d7cdd6b5
First added on: Feb 03, 2025